For the quarter ending 2025-08-31, CCEL made $7,825,432 in revenue. $749,408 in net income. Net profit margin of 9.58%.
| Income Statement | 2025-08-31 | 2025-05-31 | 2024-11-30 | 2024-08-31 |
|---|---|---|---|---|
| Revenue | 7,825,432 | 7,928,843 | 7,950,502.333 | 8,066,715 |
| Change in fair value of contingent consideration | - | - | -3,302.667 | 12,702 |
| Impairment of investment | - | - | -77,000 | - |
| Cost of sales | 1,801,419 | 1,856,539 | 1,940,635.333 | 2,125,846 |
| Selling, general and administrative expenses | 3,876,159 | 4,257,857 | 4,790,477.667 | 4,149,785 |
| Impairment of investment-Tianhe Stem Cell Biotechnologies Inc | 0 | 0 | - | - |
| Research, development and related engineering | 61,625 | 131,711 | 349,534.333 | 193,933 |
| Depreciation and amortization | 185,693 | 190,102 | 96,321 | 194,559 |
| Total costs and expenses | 5,924,896 | 6,436,209 | 7,276,332.333 | 6,676,825 |
| Operating income | 1,900,536 | 1,492,634 | 696,798 | 1,389,890 |
| (losses) gains on marketable securities | -193,886 | -379,332 | 184,531 | 522,458 |
| Gain on interest rate swap | 0 | 0 | 26,471.75 | - |
| Other income | 17,565 | 12,927 | 1,867.333 | 981 |
| Interest expense | 538,219 | 551,126 | 443,740 | 533,464 |
| Total other income (expense) | -714,540 | -917,531 | -222,046 | -10,025 |
| Income before income tax expense | 1,185,996 | 575,103 | 474,752 | 1,379,865 |
| Income tax expense | 436,588 | 219,318 | 691,280 | 328,186 |
| Net income | 749,408 | 355,785 | -216,528 | 1,051,679 |
| Earnings per share, basic | 0.09 | 0.04 | -0.027 | 0.13 |
| Earnings per share, diluted | 0.09 | 0.04 | -0.027 | 0.13 |
| Weighted average number of shares outstanding, basic | 8,057,780 | 8,080,161 | 22,910 | 8,061,946 |
| Weighted average number of shares outstanding, diluted | 8,073,654 | 8,125,720 | 12,991.667 | 8,173,535 |
CRYO CELL INTERNATIONAL INC (CCEL)
CRYO CELL INTERNATIONAL INC (CCEL)